EUVIMEDEUVIMED entdecken
Fallbericht

Successful Isavuconazole Treatment for Pulmonary Mucormycosis in a Patient Intolerant to Liposomal Amphotericin B with Pharmacokinetic Insights: A Case Report

Takeo Yasu, Makoto Hoshino, Naoya Sakamoto, Masayuki Kobayashi

Chemotherapy · 2024

DOI: 10.1159/000539652 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Chemotherapy, 2024. Verfasst von Takeo Yasu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Mucormycosis, Nitriles, Triazoles, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mucormycosis presents a diagnostic challenge characterized by high morbidity and mortality rates due to its swift and pervasive nature, which leads to extensive tissue destruction and dissemination. Immunocompromised individuals, notably those with hematological malignancies, are at a heightened risk. First-line antifungal agents include liposomal amphotericin B (L-AMB), posaconazole, and isavuconazole (IVZ), which offer advantages, such as minimal drug interactions and a favorable safety profile. However, the necessity and efficacy of therapeutic drug monitoring (TDM) of IVZ remain unclear. Case Presentation: We report a successful case of IVZ therapy in a patient who was intolerant of L-AMB, highlighting the efficacy and pharmacokinetics of IVZ in treating pulmonary mucormycosis. Pharmacokinetic analysis revealed steady plasma IVZ concentrations, emphasizing the importance of monitoring IVZ levels, particularly in patients undergoing renal replacement therapy.

Conclusion

This case highlights the efficacy of IVZ therapy for mucormycosis and the potential utility of TDM in a specific patient population. Further research is needed to elucidate the optimal IVZ dosing and monitoring strategies to ensure safe and efficacious treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisNitrilesTriazolesPyridinesAntifungal AgentsAmphotericin BHumansMaleDrug MonitoringMiddle AgedImmunocompromised HostLung Diseases, Fungal

Stichwörter der Autor:innen

IsavuconazolePharmacokineticsPulmonary mucormycosisRenal replacement therapyTherapeutic drug monitoring

Substanzen

isavuconazoleNitrilesTriazolesPyridinesAntifungal AgentsAmphotericin Bliposomal amphotericin B

Autor:innen und Institutionen

  • Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan.
  • Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan.
  • Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
  • Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.

Zitieren

APA

Yasu, T., Hoshino, M., Sakamoto, N., & Kobayashi, M. (2024). Successful Isavuconazole Treatment for Pulmonary Mucormycosis in a Patient Intolerant to Liposomal Amphotericin B with Pharmacokinetic Insights: A Case Report. Chemotherapy. https://doi.org/10.1159/000539652

Vancouver

Yasu T, Hoshino M, Sakamoto N, Kobayashi M. Successful Isavuconazole Treatment for Pulmonary Mucormycosis in a Patient Intolerant to Liposomal Amphotericin B with Pharmacokinetic Insights: A Case Report. Chemotherapy. 2024. doi:10.1159/000539652

BibTeX
@article{Yasu2024,
  author = {Yasu, Takeo and Hoshino, Makoto and Sakamoto, Naoya and Kobayashi, Masayuki},
  title = {Successful Isavuconazole Treatment for Pulmonary Mucormycosis in a Patient Intolerant to Liposomal Amphotericin B with Pharmacokinetic Insights: A Case Report},
  journal = {Chemotherapy},
  year = {2024},
  doi = {10.1159/000539652}
}
Kostenlos starten →